SGLT inhibitors on weight and body mass: A meta‐analysis of 116 randomized‐controlled trials
出版年份 2021 全文链接
标题
SGLT inhibitors on weight and body mass: A meta‐analysis of 116 randomized‐controlled trials
作者
关键词
-
出版物
Obesity
Volume 30, Issue 1, Pages 117-128
出版商
Wiley
发表日期
2021-12-22
DOI
10.1002/oby.23331
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Obesity in COVID-19: A Systematic Review and Meta-analysis
- (2021) Jamie SY Ho et al. ANNALS ACADEMY OF MEDICINE SINGAPORE
- Effects of the dual sodium‐glucose linked transporter inhibitor, licogliflozin versus placebo or empagliflozin in patients with type 2 diabetes and heart failure
- (2020) Rudolf A. Boer et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of dapagliflozin on blood pressure variability in patients with prediabetes and prehypertension without pharmacological treatment
- (2020) Cristal Díaz-Cruz et al. BLOOD PRESSURE MONITORING
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Attenuation of weight loss through improved antilipolytic effect in adipose tissue via the SGLT2 inhibitor tofogliflozin
- (2019) Akihiro Yoshida et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
- (2019) Maria J. Pereira et al. DRUGS
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- HbA1cand Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study
- (2018) Thomas Danne et al. DIABETES CARE
- Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care
- (2018) Thomas Danne et al. Diabetes Technology & Therapeutics
- The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus
- (2018) Hadi Fattah et al. DRUGS
- Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
- (2018) Hussein Al Jobori et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients with Prediabetes
- (2018) Alejandra Ramírez-Rodríguez et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK
- (2018) Krishnan Bhaskaran et al. Lancet Diabetes & Endocrinology
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
- (2017) Satish K. Garg et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis
- (2017) Xiaoling Cai et al. Obesity
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
- (2016) Michael A Weber et al. Lancet Diabetes & Endocrinology
- 6. Obesity Management for the Treatment of Type 2 Diabetes
- (2015) DIABETES CARE
- Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes
- (2015) B. Bode et al. DIABETES OBESITY & METABOLISM
- Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
- (2015) Caroline M. Apovian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes
- (2014) David Polidori et al. DIABETOLOGIA
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial
- (2014) Krzysztof Strojek et al. Diabetes Therapy
- Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
- (2013) Clifford J Bailey et al. BMC Medicine
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
- (2011) K. Strojek et al. DIABETES OBESITY & METABOLISM
- Long-Term Persistence of Hormonal Adaptations to Weight Loss
- (2011) Priya Sumithran et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
- (2009) Alessandro Liberati et al. PLOS MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started